Vaxxinity Overview
Valuation check: VAXX's ROE is -424.51%, below the sector sector average of -5.87%.
Get informed when a big investor buys or sells
+ Follow-424.51%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for VAXX is -424.51%. That is below the sector sector average of -5.87%. Investors often review this figure alongside Vaxxinity's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, VAXX currently prints -424.51% for ROE, while the sector average sits near -5.87%. That is roughly 7133.7% below the sector mean. Large gaps often invite a closer look at Vaxxinity's growth, margins, and balance sheet.
Return on Equity shows how effectively Vaxxinity converts resources into returns. At -424.51%, VAXX may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting VAXX's ROE (-424.51%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
